Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ceftriaxone
Drug ID BADD_D00405
Description Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic.[A215582] It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges[A215582], eyes[A215647], and inner ear[A215627]. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for the convenience of daily or twice-daily dosing.[A215582]
Indications and Usage Ceftriaxone is used for the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by susceptible organisms.[L15082] Organisms that are generally susceptible to ceftriaxone include S. pneumoniae, S. pyogenes (group A beta-hemolytic streptococci), coagulase-negative staphylococci, Some Enterobacter spp, H. influenzae, N. gonorrhoeae, P. mirabilis, E. coli, Klebsiella spp, M. catarrhalis, B. burgdorferi, and some oral anaerobes.[A215582]
Marketing Status approved
ATC Code J01DD04
DrugBank ID DB01212
KEGG ID D07659
MeSH ID D002443
PubChem ID 5479530
TTD Drug ID D07ACT
NDC Product Code 72572-061; 25021-105; 25021-107; 44567-700; 63323-346; 0143-9859; 66794-213; 71205-593; 72572-062; 66794-215; 70594-098; 44567-701; 66794-211; 70518-3355; 25021-106; 0143-9856; 44567-702; 66794-214; 70594-094; 70594-097; 0264-3155; 66794-212; 44567-703; 0264-3153; 70594-095; 70594-096; 0143-9678; 0143-9857; 0143-9858
UNII 75J73V1629
Synonyms Ceftriaxone | Ceftriaxon | Cefatriaxone | Ceftriaxone, Disodium Salt, Hemiheptahydrate | Ceftrex | Ceftriaxon Curamed | Ceftriaxon Hexal | Ceftriaxona Andreu | Ceftriaxona LDP Torlan | Ceftriaxone Irex | Ceftriaxone Sodium | Ceftriaxone Sodium, Anhydrous | Anhydrous Ceftriaxone Sodium | Lendacin | Longacef | Longaceph | Ro13-9904 | Ro13 9904 | Ro139904 | Ro-13-9904 | Ro 13-9904 | Ro 13 9904 | Ro 139904 | Rocephin | Rocefalin | Rocephine | Rocefin | Tacex | Terbac | Ceftriaxone, Disodium Salt | Benaxona | Cefaxona
Chemical Information
Molecular Formula C18H18N8O7S3
CAS Registry Number 73384-59-5
SMILES CN1C(=NC(=O)C(=O)N1)SCC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Autoimmune disorder10.04.04.0030.004457%
Hepatic lesion09.01.08.0050.011141%Not Available
Metabolic encephalopathy17.13.01.001; 14.11.01.0130.020946%Not Available
Ureteral disorder20.06.01.0040.006685%Not Available
Renal impairment20.01.03.010--Not Available
Heparin-induced thrombocytopenia24.01.01.020; 10.02.01.007; 01.08.01.0040.004457%Not Available
Hyperamylasaemia14.11.01.0030.011141%Not Available
Infusion site extravasation08.02.05.007; 12.07.05.0080.019609%
Immune reconstitution inflammatory syndrome10.02.01.043; 08.06.02.0140.020054%Not Available
Bone marrow failure01.03.03.0050.017826%
Mixed liver injury09.01.07.0150.008913%Not Available
Bronchial secretion retention22.03.02.0080.004457%Not Available
Treatment failure08.06.01.0170.082000%Not Available
Liver injury12.01.17.012; 09.01.07.0220.020054%Not Available
Adverse reaction08.06.01.0180.004457%Not Available
Low birth weight baby18.04.02.0030.031196%Not Available
Urinary casts present13.13.02.009--Not Available
Cholestatic liver injury09.01.07.0160.004457%Not Available
Hypertransaminasaemia09.01.02.0050.022283%Not Available
Oropharyngeal discomfort22.12.03.015; 07.05.05.0080.006685%Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.004--
Kounis syndrome02.02.02.020; 24.04.04.020; 10.01.03.0370.037881%Not Available
Acute kidney injury20.01.03.0160.396187%
Use of accessory respiratory muscles22.12.02.0150.004457%Not Available
Langerhans' cell histiocytosis09.01.08.018; 22.01.01.016; 16.21.04.003; 15.09.03.008; 01.13.04.0030.004457%Not Available
Hypoxic-ischaemic encephalopathy24.04.06.021; 22.02.02.011; 17.13.02.0060.004457%Not Available
Posterior reversible encephalopathy syndrome17.13.02.0070.004457%
Drug-induced liver injury12.03.01.044; 09.01.07.0230.133696%Not Available
Peripheral artery thrombosis24.01.02.0100.004457%Not Available
Drug reaction with eosinophilia and systemic symptoms12.03.01.064; 23.03.05.005; 10.01.01.0210.122555%Not Available
The 14th Page    First    Pre   14 15 16    Next   Last    Total 16 Pages